Search Results - "Abousaud, Marin"

Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings by Abousaud, Marin I, Rush, Marie C, Rockey, Michelle

“…Introduction At Wake Forest Baptist Health, an adult tumor lysis syndrome pocket card was created in order to optimize management of tumor lysis syndrome and…”
Get full text

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States by Yang, Fan, Shay, Chloe, Abousaud, Marin, Tang, Chris, Li, Yamin, Qin, Zhaohui, Saba, Nabil F, Teng, Yong

“…Immune-related adverse events (irAEs) are a common phenomenon in cancer patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity…”
Get full text

A Systematic Review of Intravaginal Diazepam for the Treatment of Pelvic Floor Hypertonic Disorder by Stone, Rebecca H., Abousaud, Marin, Abousaud, Aseala, Kobak, William

“…This systematic review evaluates the efficacy of intravaginal diazepam in treating chronic pelvic pain and sexual dysfunction associated with high‐tone pelvic…”
Get full text

Long-Term Follow-up of Parenteral Bevacizumab In Patients with Recurrent Respiratory Papillomatosis by Ballestas, Samir A, Hidalgo Lopez, Julio, Klein, Adam M, Steuer, Conor, Shin, Dong M, Abousaud, Marin, Schmitt, Nicole C, Teng, Yong, Saba, Nabil F, Tkaczuk, Andrew T

“…The clinical course of recurrent respiratory papillomatosis (RRP) varies from spontaneous remission to severe airway obstruction with wide variability in…”
Get full text

Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement by So, Raymond J., Hidalgo Lopez, Julio C., Ballestas, Samir A., Klein, Adam M., Steuer, Conor, Shin, Dong M., Abousaud, Marin, Teng, Yong, Saba, Nabil F., Tkaczuk, Andrew T., Schaefer, Eric S., Seiwert, Tanguy Y., McClellan, Kim, Best, Simon R.

“…Objectives Pulmonary papillomatosis is a rare but severe manifestation of recurrent respiratory papillomatosis (RRP). Efficacy data of systemic bevacizumab for…”
Get full text

Abnormal Skeletal Muscle Regeneration plus Mild Alterations in Mature Fiber Type Specification in Fktn-Deficient Dystroglycanopathy Muscular Dystrophy Mice by Foltz, Steven J, Modi, Jill N, Melick, Garrett A, Abousaud, Marin I, Luan, Junna, Fortunato, Marisa J, Beedle, Aaron M

“…Glycosylated α-dystroglycan provides an essential link between extracellular matrix proteins, like laminin, and the cellular cytoskeleton via the…”
Get full text

Assessing survival outcomes of patients with oral tongue squamous cell carcinoma: Focus on age, sex, and stage by Pamulapati, Saagar, Abousaud, Marin, Li, Yixuan, Ekpenyong, Asari, Rudra, Soumon, Remick, Jill S., Bates, James E., Stokes, William A., McDonald, Mark W., Schmitt, Nicole C., El‐Deiry, Mark W., Patel, Mihir R., Steuer, Conor E., Switchenko, Jeffrey M., Shin, Dong M., Teng, Yong, Hammond, Anthea, Saba, Nabil F.

“…Background The purpose of this study was to provide further insights into whether age and/or sex are associated with prognosis in oral tongue squamous cell…”
Get full text

489 Statin drugs augment tumor response to anti-PD-1 immune check point blockade in head and neck cancer patients by Kristoff, Tyler J, Evans, Sean, Nayi, Pranay, Abousaud, Marin, Steuer, Conor, Shin, Dong, Saba, Nabil F, Schmitt, Nicole C

“…BackgroundAnti-programmed cell death protein-1 (PD-1) immune checkpoint blockade (ICB) has become a common first line treatment for head and neck squamous cell…”
Get full text

Evaluation of bleeding risk between apixaban and rivaroxaban in patients with gastrointestinal cancer by Gundersen, Parker, Basilio, Alexa, Draper, Amber, Tiao, Emily, Abousaud, Marin Ibrahim, Gbolahan, Olumide B.

“…e16323 Background: Patients with cancer are at a higher risk for developing venous thromboembolisms (VTEs), leading to further complications. The National…”
Get full text

Retrospective analysis of digital biomarker predictability of immune checkpoint inhibitor therapy outcomes in patients with NSCLC by Abousaud, Marin, Frame, David, Harvey, R. Donald, Kaddoura, Layan, Ekpenyong, Asari, Abousaud, Aseala, Steuer, Conor Ernst, Derstine, Brian, Wang, Nicholas C., Mackler, Emily R.

“…e14713 Background: Immune checkpoint inhibitor (ICI) therapy (pembrolizumab monotherapy and pembrolizumab combined with platinum-based chemotherapy) is…”
Get full text

Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial by Saba, Nabil F., Steuer, Conor E., Ekpenyong, Asari, McCook-Veal, Ashley, Magliocca, Kelly, Patel, Mihir, Schmitt, Nicole C., Stokes, William, Bates, James E., Rudra, Soumon, Remick, Jill, McDonald, Mark, Abousaud, Marin, Tan, Aik Choon, Fadlullah, Muhammad Zaki Hidayatullah, Chaudhary, Ritu, Muzaffar, Jameel, Kirtane, Kedar, Liu, Yuan, Chen, Georgia Z., Shin, Dong M., Teng, Yong, Chung, Christine H.

“…Anti-programmed cell death protein 1 (PD-1) therapy is a standard of care in recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). Vascular…”
Get full text

A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC) by Saba, Nabil F., Ekpenyong, Asari, McCook-Veal, Ashley, Patel, Mihir, Schmitt, Nicole Cherie, Stokes, William A., Bates, James Edward, Rudra, Soumon, Abousaud, Marin Ibrahim, Muzaffar, Jameel, Kirtane, Kedar, Teng, Yong, Steuer, Conor Ernst, Shin, Dong Moon, Liu, Yuan, Chung, Christine H.

“…6008 Background: Pembrolizumab (pembro) is an immune checkpoint inhibitor (ICI) approved for treating pts with recurrent/metastatic (RM) HNSCC. Cabozantinib…”
Get full text

Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial by Saba, Nabil F., Steuer, Conor E., Ekpenyong, Asari, McCook-Veal, Ashley, Magliocca, Kelly, Patel, Mihir, Schmitt, Nicole C., Stokes, William, Bates, James E., Rudra, Soumon, Remick, Jill, McDonald, Mark, Abousaud, Marin, Tan, Aik Choon, Fadlullah, Muhammad Zaki Hidayatullah, Chaudhary, Ritu, Muzaffar, Jameel, Kirtane, Kedar, Liu, Yuan, Chen, Georgia Z., Shin, Dong M., Teng, Yong, Chung, Christine H.

Get full text

DDRE-17. INITIAL CLINICAL EXPERIENCE USING OSIMERTINIB IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS WITH EGFR ALTERATIONS by Abousaud, Marin, Faroqui, Naqeeb, Hsu, Fang-Chi, Lesser, Glenn, Strowd, Roy, Ramkissoon, Shakti, Kwatra, Madan, Houston, Kristin Strickland, Carter, Annette, DeTroye, Alisha

“…Abstract EGFR alterations are commonly observed in malignant gliomas (MG), especially glioblastomas, making this pathway an appealing therapeutic target…”
Get full text

Efficacy and safety of a modified daratumumab/bortezomib/dexamethasone regimen using once weekly bortezomib in relapsed refractory multiple myeloma by Abousaud, Marin, Dressler, Emily, Duda, Jessica, Johnson, Emily, Kennedy, LeAnne, Rodriguez, Cesar

Get full text

Altered Fiber Types in Regenerated Muscle of Fktn ‐KO Muscular Dystrophy Mice by Beedle, Aaron, Modi, Jill, Melick, Garrett, Abousaud, Marin, Fortunato, Marisa, Foltz, Steven

“…Abstract only Secondary dystroglycanopathies are a class of muscular dystrophy caused by mutations in genes, including fukutin ( FKTN ), that are important for…”
Get full text